ReviewFrontiers in oncology2026
Redefining drug discovery: AI-driven strategies for efficient cancer therapeutics.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The practice of artificial intelligence has recently expanded several social spheres, with the pharmaceutical domain leading the way. Given that AI can facilitate rational drug design, it is plausible to envision its involvement in developing pharmaceutical products from the laboratory to the patient's bedside. AI recognizes hit and lead compounds, followed by validation of therapeutic targets and optimization of molecular design. Artificial intelligence significantly impacts drug discovery and development processes, including target identification, molecule design, drug-drug interactions, drug repurposing, optimization of clinical trials, drug toxicity prediction, drug formulation, and delivery. AI-assisted approaches are progressively being employed for identification and prioritization of targets, biomarker discovery and virtual screening as well as prediction for the interaction of protein and ligand and their molecular properties followed by ADMET screening, molecular design and repurposing to be suited for clinical trial optimization. The significance of automation will be boosted by adopting the most recent artificial intelligence-based technologies, reducing the time it takes for drugs to be available in the market with improved quality, production process safety, and resource utilization. The application of artificial intelligence may not only aid in rapid decision-making but can also enhance the process of incorporating the newly discovered drug into the optimum dosage form, which leads to faster manufacturing of higher-quality drugs and ensures consistency among batches. The potential of artificial intelligence in drug discovery and development, has been explored in this review, encircling several stages from identification of target to its clinical applications, followed by drug development approaches encompassing the future of artificial intelligence in the pharmaceutical sector, along with crosstalk on the tools and tactics used to enforce artificial intelligence, current difficulties, and respective solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.